BPC-157: Everything You Need to Know—Benefits, Risks, Dosing, & Delivery Methods
A physician's walkthrough of BPC-157 covering preclinical findings, the thin human evidence, his stated cancer concern, and his views on forms, doses, timing, cycle length and sourcing.
Key moments
Tap a moment to play the video from there.
- 0:35What BPC-157 is and how it worksStillson describes it as a 15 amino acid peptide from gastric juice, and says it works through nitric oxide, VEGF and collagen synthesis.
- 2:48Musculoskeletal findings in preclinical studiesHe cites preclinical studies on tendon, ligament, muscle and bone injury, and says it looks most promising for tendons and ligaments.
- 4:44Gut health findingsHe describes preclinical work on colitis, surgical joins in the bowel, ulcers and NSAID-related injury.
- 6:44Brain and nerve findingsHe covers preclinical studies on stroke, brain injury, nerve and spinal cord injury, and mood-related outcomes.
- 10:10The human data is thinStillson says only three detailed human studies exist, all small and short, and that one planned safety trial was never published.
- 13:13Angiogenesis and cancer concernHe explains why he considers VEGF-driven blood vessel growth a theoretical concern and who he says should avoid BPC-157.
- 15:39His recommendation and sourcing viewHe says he would reserve it for short courses after a stubborn injury, with cancer screening first, and does not recommend injectables from research suppliers.
- 18:34Injectable, oral and topical formsHe compares estimated bioavailability across forms and says local injection is not required.
- 23:08Dosing and conversionHe converts a preclinical dose to a human equivalent and lists the anecdotal ranges for injectable and oral use.
- 29:55Supplier testing checklistHe lists the third-party tests he would want on a certificate of analysis for injectable and oral products.
What the video says
Quinn Stillson, a physician, explains BPC-157 as a 15 amino acid peptide derived from human gastric juice. He notes it is not approved for human use, so injectable versions are sold for research use only. He says its main mechanism is increased blood flow to injured tissue, through more nitric oxide and higher VEGF expression, plus added collagen synthesis and more growth hormone receptors on fibroblasts.
He then reviews preclinical studies he says showed benefits for tendon, ligament, muscle and bone injury, for gut conditions such as colitis, ulcers and NSAID-related injury, and for stroke, brain injury, nerve injury and mood-related outcomes. He also mentions cardiovascular effects as postulated, based mostly on preclinical work.
The middle of the talk covers safety. Stillson says preclinical studies reported no toxic doses, but he counts only three detailed peer-reviewed human studies, each very small and short, and one planned two-week oral safety trial whose results were never published. His main stated concern is that the same angiogenesis mechanism could, in theory, support tumor growth. He says no study shows this, but long-term follow-up is missing. He advises avoiding it with active cancer, a precancerous diagnosis or a strong family history of cancer, and says he does not recommend injectable use until it can come from a compounding pharmacy.
The last third covers practicalities he presents as theoretical. He ranks subcutaneous injection above oral and topical for systemic exposure, prefers oral for gut issues, and suggests an arginate salt for oral use. He walks through a rat-to-human dose conversion and anecdotal ranges, then gives his views on timing, a 4 to 8 week course with a break, and the third-party tests he would look for in a supplier.
On each compound
BPC-1570:35
Stillson describes BPC-157 as a 15 amino acid peptide derived from gastric juice and not approved for human use. He covers its proposed mechanisms, preclinical findings, thin human data, his cancer concern, and his views on forms, dosing, timing and cycle length.
See how your DNA reads BPC-157What this video doesn’t settle
- Almost all the benefits he describes come from preclinical studies, so the video does not establish that they apply to people.
- The three human studies he cites were tiny and short, and he says they gave little safety data.
- The cancer concern is his theoretical reasoning, and he says no study has shown the effect.
Questions this video answers
What does Quinn Stillson say about BPC-157 safety?
He says preclinical studies reported no toxic doses, but he knows of only three detailed human studies, all small and short, with weak safety data. He also points to an unpublished two-week oral trial and says the lack of long-term human data leaves safety unknown.
Why does Stillson link BPC-157 to cancer concerns?
He says BPC-157 raises VEGF and promotes new blood vessel growth, a pathway that tumors use to grow. He says no study shows this effect, but without long-term follow-up he cannot rule it out, so he advises people with active or precancerous disease or strong family history to avoid it.
Does Stillson say injectable or oral BPC-157 is better?
He says subcutaneous injection likely gives the highest systemic exposure and is better for deep musculoskeletal injuries. He prefers the oral form for gut issues, suggests an arginate salt, and says injection need not be near the injury site.
What dose and duration does Stillson discuss for BPC-157?
He says there is no established human dose. He describes anecdotal ranges of 250 to 500 micrograms per day subcutaneous and 500 to 1,000 micrograms per day oral, and suggests 4 to 8 weeks followed by a 4 to 8 week break.
What testing does Stillson want from a BPC-157 supplier?
For injectables he says to look for batch-specific third-party results for identity and purity, endotoxin (USP 85) and sterility (USP 71). For oral products he says purity and identity testing matters most.
Video by Quinn Stillson MD on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
